{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-104164","form_type":"8-K","ticker":"TNYA","cik":"0001858848","company_name":"Tenaya Therapeutics, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.406564+00:00","generated_at":"2026-05-17T19:57:21.591451+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tenaya Therapeutics Q2 net loss $23.3M; cash runway into H2 2026; TN-201/401 data Q4 2025","bullets":["Net loss $23.3M ($0.14 loss per share) vs $29.4M ($0.34) in Q2 2024.","Cash, equivalents and marketable securities $71.7M as of June 30, 2025; runway into H2 2026.","TN-201 for HCM: Cohorts 1 & 2 enrollment complete; DSMB allows expansion; data readout Q4 2025.","TN-401 for ARVC: Cohort 1 enrolled; DSMB recommends dose escalation; first patient dosed in Cohort 2; data Q4 2025.","R&D expense $17.4M vs $22.6M YoY; G&A $6.7M vs $8.2M YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-104164","json":"https://secwatch.observer/filing/0000950170-25-104164.json","markdown":"https://secwatch.observer/filing/0000950170-25-104164.md","text":"https://secwatch.observer/filing/0000950170-25-104164.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858848/000095017025104164/0000950170-25-104164-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858848/000095017025104164/tnya-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:57:21.591451+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}